Working… Menu

A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma (FIREFLY-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04775485
Recruitment Status : Recruiting
First Posted : March 1, 2021
Last Update Posted : November 29, 2021
Pacific Pediatric Neuro-Oncology Consortium
Information provided by (Responsible Party):
DOT Therapeutics-1 Inc. ( Day One Biopharmaceuticals, Inc. )

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 30, 2023
Estimated Study Completion Date : February 28, 2024